Blend Therapeutics appoints CEO
This article was originally published in Scrip
Executive Summary
Watertown, Massachusetts-based Blend Therapeutics, a biopharmaceutical company developing two classes of targeted anti-cancer medicines for the treatment of patients with solid tumor cancers, has named Drew Fromkin president and CEO.